Your browser doesn't support javascript.
loading
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal, Walter; Oosterkamp, Hendrika M; Walenkamp, Annemiek M E; Dubbink, Hendrikus J; Beerepoot, Laurens V; Hanse, Monique C J; Buter, Jan; Honkoop, Aafke H; Boerman, Dolf; de Vos, Filip Y F; Dinjens, Winand N M; Enting, Roelien H; Taphoorn, Martin J B; van den Berkmortel, Franchette W P J; Jansen, Rob L H; Brandsma, Dieta; Bromberg, Jacoline E C; van Heuvel, Irene; Vernhout, René M; van der Holt, Bronno; van den Bent, Martin J.
Afiliação
  • Taal W; Department of Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Oosterkamp HM; Department of Medical Oncology, Medical Center Haaglanden, The Hague, Netherlands.
  • Walenkamp AM; Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands.
  • Dubbink HJ; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Beerepoot LV; Department of Oncology, St Elisabeth Ziekenhuis, Tilburg, Netherlands.
  • Hanse MC; Department of Neurology, Catharina Hospital Eindhoven, Netherlands.
  • Buter J; Department of Oncology, VU University Medical Center, Amsterdam, Netherlands.
  • Honkoop AH; Department of Internal Medicine, Isala Kliniek, Zwolle, Netherlands.
  • Boerman D; Department of Neurology, Rijnstate, Arnhem, Netherlands.
  • de Vos FY; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, Netherlands.
  • Dinjens WN; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Enting RH; Department of Neurology, University Medical Center Groningen, Groningen, Netherlands.
  • Taphoorn MJ; Department of Neurology, Medical Center Haaglanden, The Hague, Netherlands.
  • van den Berkmortel FW; Department of Oncology, Atrium MC Parkstad, Heerlen, Netherlands.
  • Jansen RL; Department of Oncology, Maastricht Universitair Medisch Centrum, Netherlands.
  • Brandsma D; Department of Neuro-oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
  • Bromberg JE; Department of Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • van Heuvel I; Department of Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Vernhout RM; Clinical Trial Centre, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • van der Holt B; Clinical Trial Centre, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • van den Bent MJ; Department of Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.
Lancet Oncol ; 15(9): 943-53, 2014 Aug.
Article em En | MEDLINE | ID: mdl-25035291
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Anticorpos Monoclonais Humanizados / Lomustina / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Anticorpos Monoclonais Humanizados / Lomustina / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Holanda